Neuroblastoma, a tumor of peripheral neural crest origin, is a common and lethal tumor of childhood. Amplification of the transcription factor MYCN occurs frequently in this tumor, and correlates with advanced disease. We generated a transgenic mouse model for high-risk neuroblastoma by directing expression of a MYCN transgene to the peripheral neural crest, under control of the Tyrosine Hydroxylase (TH) promoter. Genetic analyses identified conserved genetic changes between human and murine tumors, and argue that mice transgenic for TH-MYCN represent an important genetic model for childhood neuroblastoma. We hypothesize that the additional genetic and epigenetic lesions which contribute to neuroblastoma formation in the mouse will be in genes relevant to neuroblastoma in children. The long term objective of this application is to identify genetic and epigenetic changes in murine and human neuroblastoma. Genes identified in this study may reveal novel mechanisms and pathways relevant to human MYCN-amplified neuroblastoma, ultimately leading to novel therapeutic targets. Strains of mice differ in susceptibility to tumors. Mice transgenic for TH-MYCN in strain FVB/N do not develop tumors, nearly all transgenic mice in strain 129/SvJ die of tumors by 4 months of age, and 129/SvJ FVB/N F1 mice show 4% penetrance. These observations suggest that structural or epigenetic changes in germ line modifier genes differ between strains, interact with Mycn, and underlie the differences in susceptibility between strains. These strain-specific differences provide a critical resource to identify secondary genetic and epigenetic events important in both murine and human neuroblastoma. We propose to mobilize a powerful insertional mutagen, the vertebrate Sleeping Beauty (SB) transposon, and to combine use of somatic insertional mutagenesis with comparative genomic hybridization and modifier genetics to identify genes that influence susceptibility to tumors in murine neuroblastoma.
Aim 1 uses SB transposon-based insertional mutagenesis to accelerate oncogenic mutations and to increase penetrance of tumors in F1 mice.
Aim 2 applies array-based comparative genomic hybridization to characterize copy-number abnormalities in both spontaneous and transposon-induced tumors in F1 mice, to characterize strain-specific methylation patterns, and to identify epigenetic changes in tumors.
Aim 3 validates and characterizes candidate genes in-vitro and in-vivo, prioritizing based on the involvement of specific candidate genes in human neuroblastoma.
Neuroblastoma is a common and frequently lethal tumor of children, for which current therapies are often ineffective. The long term objective of this application is to use a mouse model for neuroblastoma developed in our laboratory to identify genes important to the development of tumors in mice and in children with this disease. Genes identified in this study are likely to reveal novel mechanisms and pathways relevant to human neuroblastoma, ultimately leading to novel therapeutic targets.
|Hackett, Christopher S; Quigley, David A; Wong, Robyn A et al. (2014) Expression quantitative trait loci and receptor pharmacology implicate Arg1 and the GABA-A receptor as therapeutic targets in neuroblastoma. Cell Rep 9:1034-46|
|Swartling, Fredrik J; Hede, Sanna-Maria; Weiss, William A (2013) What underlies the diversity of brain tumors? Cancer Metastasis Rev 32:5-24|
|Chanthery, Yvan H; Gustafson, W Clay; Itsara, Melissa et al. (2012) Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma. Sci Transl Med 4:115ra3|
|Fan, Qi-Wen; Weiss, William A (2012) Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors. Methods Mol Biol 821:349-59|
|Fan, Qi-Wen; Weiss, William A (2010) Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance. Curr Top Microbiol Immunol 347:279-96|
|Gustafson, W C; Weiss, W A (2010) Myc proteins as therapeutic targets. Oncogene 29:1249-59|
|Swarbrick, Alexander; Woods, Susan L; Shaw, Alexander et al. (2010) miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. Nat Med 16:1134-40|
|Collier, Lara S; Adams, David J; Hackett, Christopher S et al. (2009) Whole-body sleeping beauty mutagenesis can cause penetrant leukemia/lymphoma and rare high-grade glioma without associated embryonic lethality. Cancer Res 69:8429-37|
|Cheng, Christine K; Fan, Qi-Wen; Weiss, William A (2009) PI3K signaling in glioma--animal models and therapeutic challenges. Brain Pathol 19:112-20|
|Weiss, William A; Taylor, Stephen S; Shokat, Kevan M (2007) Recognizing and exploiting differences between RNAi and small-molecule inhibitors. Nat Chem Biol 3:739-44|
Showing the most recent 10 out of 11 publications